Urgency over clinical trials and medtech laws leaves P&R transparency out in the cold
This article was originally published in Scrip
The race is on to get three major pieces of draft laws through the EU legislative process before the European Parliament elections in May 2014, with feverish behind-the-scenes negotiations taking place to thrash out a number of controversial issues that have arisen, mostly, from amendments by the European Parliament's environment and public health (ENVI) committee.
You may also be interested in...
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.